Business
VistaGen Announces Korean Intellectual Property Office Decision to Grant PH10 Patent for Treatment of Depression
Previously completed Phase 2A clinical study of PH10 demonstrated significant antidepressant effects without psychological side effects or safety concerns
About this update from Vistagen Therapeutics, Inc.
[{"type":"text","content":"Previously completed Phase 2A clinical study of PH10 demonstrated significant antidepressant effects without psychological side effects or safety concerns after only one week of administration\n\n\nSOUTH SAN FRANCISCO, Calif., Dec. 10, 2020 /PRNewswire/ -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company developing new generation medicines with the potential to go beyond the current standard of care for anxiety, depression and other central nervous system (CNS) disorders, today announced that the Korean Intellectual Property Office (KIPO) in the Republic of Korea has issued a Decision to Grant Patent Application No. 10-2015-7020176 related to methods of treating depressive disorder with VistaGen's PH10, an investigational neuroactive nasal spray designed to have rapid-onset therapeutic potential in several neuropsychiatric indications involving depression, initially as potential stand-alone treatment for major depressive disorder (MDD). The patent is not set to expire earlier than 2034. \n\n \n \n \n \n \n \n\n \n\"The Republic of Korea is an important pharmaceutical market. With counterpart patents already issued in the U.S., Greater China, Europe and Japan, this patent enhances our patent protection for PH10 and is a key component of our global commercial protection strategy for PH10,\" stated Shawn K. Singh, Chief Executive Officer of VistaGen. \"Our late-stage development and commercialization strategy for PH10 is similar to our strategy for PH94B, namely, to license these rights in key pharmaceutical markets outside of North America.\"\n\"MDD affects more than 264 million adults globally and can have significant emotional, functional and economic impact on those who suffer from the disorder and their loved ones. Recent studies have also shown that there has been an exacerbation of existing depression symptoms, with U.S. adults showing three times as many symptoms of depression during the COVID-19 pandemic we are battling, making the need for better, safer alternatives for depression treatments more imperative. We believe PH10 has the potential to transform the treatment landscape for individuals with MDD in global depression markets, and we believe this patent will help protect and propel global development,\" continued Mr. Singh. \nAbout Major Depressive Disorder (MDD)MDD is a serious neurobiologically bas...